Cargando…
Industrialized GMP Production of CD34(+) Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe
Regenerative medicine now needs to pass a crucial turning point, from academic research to the market. Several sources/types of cells have been experimented with, more or less successfully. CD34(+) cells have demonstrated multipotent or even pluripotent capacities, making them good candidates for re...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209364/ https://www.ncbi.nlm.nih.gov/pubmed/35420389 http://dx.doi.org/10.1007/s12015-022-10373-5 |